Group subsidiaries:IDEAL | ELLIQUENCE
CHINESE
HOME>THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS

  •       Wang Chong
          Chairman

    He holds a Ph.D. in Biomedical Engineering from the University of Miami and a Master’s Degree in Materials Science and Chemical Engineering from the University of California, Irvine.

    He is currently the Chairman and General Manager of the company. He has held various professional roles, including General Manager and Executive Director at Shenzhen Qianhai Junsheng Innovation Management from June 2016 to October 2021, and General Manager of Suzhou Shutong Medical from November 2021 to May 2025.


  •       Hui Yiwei
          Director

    He earned an MBA from Cornell University and a Master's Degree from Tsinghua University’s PBC School of Finance.

    He is currently the Deputy General Manager of the company. He has held various professional roles, including Deputy General Manager CICG Operations from August 2016 to April 2021, and Managing Director at Xinjin Shunzhi Investment Management (Ningbo) from May 2021 to July 2022. He has served as the Executive Director of Suzhou Xinsheng Huiming Private Equity Fund Management Co., Ltd. since August 2022.


  •       Wen Chen
          Director

    He earned a Bachelor's Degree from Purdue University, USA, a Master's Degree from Washington University School of Medicine in St. Louis, USA and Durham University Business School, UK.

    He has held various professional roles, including Medical Investment Partner at Shanghai Yonghua Investment Management Co., Ltd. since March 2020. At Suzhou Shutong Medical Technology Co., Ltd. since January 2020, Chengdu Serano Medical Technology Co., Ltd. since September 2021, Shanghai CureGene Pharmaceutical Co., Ltd. since June 2021, Suzhou Luosheng Biopharmaceutical Co., Ltd. since August 2021, Shanghai Kaiyitong Medical Technology Co., Ltd. since September 2022 served as a Non-Independent Director. Served as an Independent Director at Inventisbio Co., Ltd. since December 2020 and Genor Biopharma Holdings Limited since June 2020.


  •       Jin Shiqiang
          Director

    He holds a Bachelor's Degree in Tunnel and Underground Engineering from Tongji University. He has served as a Deputy Manager of Project Department at Shanghai Electric Power Generation Engineering Co. since August 2011.


  •       Zhu Dingmi
          Independent Director

    She earned a Bachelor's Degree in Accounting and is certified as a Senior Accountant. She has served as a Chief Financial Officer at Zhejiang Aoxiang Pharmaceutical Co., Ltd. since July 2021.


  •       Liu Xuewen
          Independent Director

    He earned a Master's Degree in Law of University of International Business and Economics. He has served as a Lawyer and Director at Beijing Branch of JiaHua Law Firm since August 2020.


免责声明

欢迎访问上海凯利泰医疗科技股份有限公司(以下简称“凯利泰”)的官方网站(以下简称“本网站”)。
在浏览本网站内容前,请您仔细阅读以下声明内容。
本网站专门为医疗卫生领域的专业人员提供在线服务,若您并非该领域的专业人员,建议您退出本网站,以免网站信息对您造成不必要的困扰。
本网站发布的各类内容,均不能代替医疗卫生领域的专业人员做出的医学专业判断,也不构成针对任何医疗卫生领域问题提供的建议或意见。如遇有任何医疗卫生领域问题,您应始终寻求专业医疗卫生人员的指导。
本网站发布的某些信息中可能包含预测性的描述,这些描述旨在反映凯利泰对未来发展趋势、业务前景或市场动态等方面的愿景和预期,而非对未来发展成果的任何承诺或保证。
本网站展示的产品或服务,系基于凯利泰的国际化业务布局,可能不适用于您所在的国家或地区。如您需要了解相关产品或服务在不同国家或地区的具体情况,请您及时联系凯利泰当地的销售代表或代理商进行确认。
在访问、浏览、使用本网站的过程中,请您务必严格遵守所在国家或地区的相关法律法规。
在阅读完上述内容后,若您选择继续访问、浏览或使用本网站,即视为您已充分理解并同意接受本免责声明的所有条款。